

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07F 9/38, A61K 31/66, C07F 9/40		A1	(11) International Publication Number: WO 98/43987 (43) International Publication Date: 8 October 1998 (08.10.98)
(21) International Application Number: PCT/EP98/01707		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 24 March 1998 (24.03.98)			
(30) Priority Data: MI97A000730 27 March 1997 (27.03.97) IT			
(71) Applicant (<i>for all designated States except US</i>): BOEHRINGER MANNHEIM ITALIA S.P.A. [IT/IT]; Viale Monza, 270, I-20128 Milano (IT).			
(72) Inventors; and (75) Inventors/Applicants (<i>for US only</i>): LIVI, Valeria [IT/IT]; Viale G.B. Stucchi, 110, I-20052 Monza (IT). SPINELLI, Silvano [IT/IT]; Viale G.B. Stucchi, 110, I-20052 Monza (IT). CONTI, Marco [IT/IT]; Viale G.B. Stucchi, 110, I-20052 Monza (IT). D'ALO', Simonetta [IT/IT]; Viale G.B. Stucchi, 110, I-20052 Monza (IT). MENTA, Ernesto [IT/IT]; Viale G.B. Stucchi, 110, I-20052 Monza (IT).		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(74) Agents: SPADARO, Marco et al.; Bianchetti Bracco Minoja S.r.l., Via Rossini, 8, I-20122 Milano (IT).			
(54) Title: BIS-PHOSPHONATE CONFUGATES WITH ALKYLATING MOIETIES HAVING ANTITUMOR ACTIVITY			
(57) Abstract			
<p>The present invention relates to conjugates of 3-carboxy-4,4'-dihydroxyphosphorylbutenoic acids with alkylating agents. Such derivatives are endowed with marked antitumor activity, especially against multiple myeloma. The present invention relates as well to a process for the preparation thereof and to pharmaceutical compositions containing them.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NB	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KR	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

BIS-PHOSPHONATE CONJUGATES WITH ALKYLATING MOIETIES
HAVING ANTITUMOR ACTIVITY

The present invention relates to conjugates of 3-carboxy-4,4'-dihydroxyphosphorylbutenoic acids with alkylating agents. Such derivatives are endowed with marked antitumor activity, especially against multiple myeloma. The present invention relates as well to a process for the preparation thereof and to pharmaceutical compositions containing them.

The skeletal system is the third more common site of metastases and more than 80% of the total number of patients dead for cancer show bone tumors at the autopsy. Bone metastases account for a significant proportion of cancer-related morbidity, causing derangement in calcium metabolism and bone marrow involvement and are responsible for the consequences of most concern to patients with cancer, such as pain, pathologic fractures, compression of the spinal cord and hypercalcemia (Drew et al., Osseous complication of malignancy, Lokich, J.J. ed. Clinical cancer medicine: treatment tactics Boston: G.K. Hall Medical Publisher, 1980, 97-112).

One of the main problems to overcome in connection with the conjugates between osteotropic carriers and cytotoxic agents is the selective release of the cytotoxic agent to the bone. The molecules characterized by an amide bond may result too stable to the hydrolysis by the lysosomal enzymes. To obtain the selective release of the cytotoxin to the bone acid-labile bonds may be used. It is known that the osteoclasts generate

2

an acidic microenvironment inside the bone resorption area. The low pH value is necessary in order to remove the mineral component (the solubility of calcium hydroxyapatite depends on the pH: the complex is almost 5 totally insoluble at physiologic pH, while it dissolves at a 50 mM concentration of Ca^{++} ions at about pH = 3.5) and to remove the organic matrix by means of the lysosomal cathepsins secreted by the same cells. The lower pH measured "in vivo" was 4.7, but the average pH 10 was 6.01 (Silver A. et al., Experimental Cell Res., 175, 266-76 (1988)). The bis-phosphonates act at the osteoclast/bone interface and localize preferentially at the bone resorption sites. When the osteoclasts begin 15 the resorption process, the bis-phosphonate, as a result of the acidification, is released from the bone surface toward the resorption area (Rodan G.A., Bone, 1, S1-S6, 1992). In this way an acid labile conjugate may be hydrolyzed and the cytotoxin may be selectively released inside the resorption area.

20 Moreover it is known that the tumor cells are able to stimulate the osteoclast's resorption activity, which causes a continuous acidification of the resorption area. Pro-drugs of daunomycin are known which contain the cis-aconic acid as a spacer between the cytotoxin 25 and the protein carrier (Shen W.C. et al., Biochem. and Biophysical Res. Comm., 102, 1048-54, 1981). It is reported that such molecules are stable in plasma at pH 7.4, while are hydrolyzed in the lysosomal compartment at pH < 5.5. Such an effect is accomplished by means of 30 the ability of the free carboxyl group of the aconitic acid to react on the amide bond formed by the other

3

carboxyl group with the cytotoxin, by catalysing its hydrolysis.

Gem-diphosphonic acids and salts thereof are known and employed in the therapy of the osteoporosis and in
5 the treatment of bone resorption (see EP 096 931, EP 252 504, BE 896.453, BE 903.519, DE 3.016.289, DE 3.540.150, DE 2.534.391, DE 3.512.536). However none of the above compounds is described to possess antitumor activity.

DE 3.425.812 (Blum et al.) describes derivatives of
10 1,1-diphosphonic acids, characterized by a bis[(haloalkyl)amino]phenyl residue, as agents useful in the treatment of bone tumors.

In WO 88/06158 are moreover described diphosphonic analogues of methotrexate as agents useful in the
15 treatment of bone tumors.

In WO 92/18512 are described conjugates of melphalan with gem-diphosphonic acids, in which the two reactive groups are linked by amino acids.

Our research was addressed toward the modification
20 of the structure of aconitic acid in order to confer affinity for the bone tissue and toward the coupling of the so obtained carriers with alkylating residues.


We have found that by coupling a diphospho-aconitic carrier with a cytotoxic agent, compounds exploiting a
25 marked affinity for the bone tissue are obtained. Such compounds are endowed with a high antitumor activity, in particular against multiple myeloma.

Human multiple myeloma is a circulating tumor which hits the plasma cells. One of its target organs is bone
30 marrow, from which the tumor invades the surrounding bone tissue and causes serious pathological consequences

4

to the patient, such as pain and fractures. Although melphalan exploits activity against the multiple myeloma, it is not able to cure the secondary bone tumor. It is therefore evident that to have found 5 compounds able to cure this latter too is a noteworthy clinical advantage. It should be noticed that any bis-phosphonate in the state of the art has been shown active against the multiple myeloma.

The present invention relates to compounds of the 10 general formula (I):



wherein:

20 - R , R_1 and R_2 are independently selected in the group consisting of hydrogen, methyl, ethyl, propyl, butyl, which can be linear or branched, with the proviso that R_1 cannot be tert-butyl;

- X is chlorine, bromine or iodine;

25 enantiomers, racemates, diastereoisomers and mixtures thereof, as well as salts thereof with pharmaceutically acceptable bases.

The $C=C$ double bond in the aconitic residue as shown in formula (I) has a purely indicative 30 stereochemistry, being included in the present invention both cis and trans stereoisomers, wherein "cis" or

5

"trans" relates to the relative position of the carboxyl and carboxamide groups.

Preferred compounds of formula (I) are those in which X is chlorine.


5 Other preferred compounds of formula (I) are those in which R, R₁ and R₂ are hydrogen.

Particularly preferred compounds of formula (I) are those in which the C=C double bond in the aconitic residue has a cis stereochemistry.

10 The compounds of formula (I) can be prepared by means of a process which comprises the following synthesis steps (where not expressly specified, the C=C double bonds stereochemistry is purely indicative):

(a) reaction of a compound of formula (II):


15



in which the R' groups are linear (C₁-C₄)alkyl groups,
20 with a compound of formula (III):



in which the R₁' groups are linear (C₁-C₄)alkyl groups,
25 in the presence of a base, to give an intermediate of formula (IV):




30

The compounds of formula (IV) are known compounds

6
 [J. Org. Chem., 45(13), 2698-2703 (1980)].


(b) hydrolysis of the R_1' ester groups, preferably in alkaline conditions, to give the intermediates of formula (V):

5




10 optionally in the form of salts with the used base;
 (c) cyclization reaction of intermediates of formula (V) in the presence of a dehydrating agent to give the anhydrides of formula (VI):

15



15 (d) condensation reaction of an anhydride of formula (VI) with a compound of formula (VII):

25




to give the compounds of formula (VIII):

30

7

5




(VIII)

(e) optional esterification of the free carboxyl group of a compound of formula (VIII) to give the compounds of formula (IX):

10

15



Compounds of formula (IX) in which R is hydrogen may be obtained by esterification of the free carboxyl group of a compound of formula (VIII) in which R is

20 tert-butyl and subsequent hydrolysis of the tert-butyl group;

(f) hydrolysis of the phosphonic esters of a compound of formula (VIII) or (IX) to give the wanted compounds of formula (I).

The condensation reaction of step (a) is preferably performed in inert solvents such as for example benzene or toluene, and in the presence of a strong base, such as for example a hydride of an alkali or alkaline-earth metal, at temperatures ranging from -10°C and the boiling point of the solvent, preferably between 0°C and

8

room temperature. A slight excess of intermediate of formula (III) is preferred.

The hydrolysis reaction of step (b) is preferably performed in the presence of an inorganic base, such as 5 for example a hydroxide of an alkaline or alkaline-earth metal, in water, an alcohol or mixtures thereof. The temperature can vary from 0°C to 70°C, preferably at room temperature.

10 The cyclization reaction of step (c) is preferably performed in the presence of a dehydrating agent such as for example a carbodiimide or an anhydride, in an inert solvent such as for example an ether (dimethoxyethane, tetrahydrofuran) and at temperatures ranging from -10°C to 50°C, preferably between 0°C and room temperature. A 15 preferred dehydrating agent is trifluoroacetic anhydride.


20 The condensation reaction of step (d) is preferably performed using until 50% excess of intermediate of formula (VI) and in the presence of a base, such as for example an organic base (trialkylamine) in large excess (5-15 equivalents), working in a solvent, preferably a polar solvent such as acetonitrile, and at temperatures ranging from 0°C to the boiling point of the solvent, more preferably at room temperature.

25 The esterification reaction of step (e) is preferably performed in the presence of an activating agent for the carboxyl group, such as for example an anhydride or a carbodiimide, in an inert solvent. The hydrolysis of the tert-butyl group is preferably 30 performed in acidic conditions, such as for example by means of trifluoroacetic acid.

9

The hydrolysis reaction of the phosphonic esters of step (f) is preferably performed by means of trimethylsilyl iodide in an inert solvent such as for example toluene and at temperatures ranging from 0°C to 5 50°C, more preferably at room temperature.

The compounds of formula (II) can be obtained from the corresponding compounds of formula (II'):



10 by reaction with an alkyl halide of formula $\text{R}_2\text{-Alg}$, in which Alg is selected from the group consisting of chlorine, bromine and iodine, in the presence of a strong base such as for example an alkaline metal or a hydride thereof, according to the methods described for 15 example in Phosphorus, Sulphur and Silicon, 1994 (88), pp. 1-13, J.C.S., 1953, pp. 1500-1501 e Heterocycles, 1990, pp. 855-862.

The compounds of formula (III) are commercial products.

20 The compounds of formula (VII) are compounds well known to the expert in the art who works in the field of the antitumor agents. Melphalan ($\text{X}=\text{chlorine}$ and $\text{R}=\text{hydrogen}$) is a clinically used antitumor drug.

25 The compounds of the invention have been tested "in vivo" against the murine breast carcinoma Walker 256/B implanted intratibia (it). After inoculation into the bone marrow cavity of the tibia, this tumor grows inside the bone causing osteolytic lesions, paraneoplastic hypercalcaemia and by invading the surrounding tissues 30 it forms a measurable tumor mass. It is therefore possible to determine both the antitumor activity on the

10

extraosseous tumor and the anti-osteolytic effect (Cancer, 72(1), 91 (1993)).

The Walker 256/B tumor was provided by NCI Frederick Cancer Facility and was maintained in male rats CD1 by means of subcutaneous transplantation of tumor fragments of about 1 cm diameter every 10 days.

To perform the experiment, each rat was injected it with 2.5×10^6 tumor cells; all the animals were anesthetized with a mixture of 10 mg/kg of Ketalar (Park-Davis) and 5 mg/kg of Rompun (Bayer). After implantation inside the tibia, the tumor grows causing osteolytic lesions associated with an increased activity of the osteoclasts. To obtain an injectable cell suspension, the tumor fragments were decomposed by means of enzymatic digestion with type IV collagenases (Sigma) at a concentration of 400 U/ml for 20 minutes at 37°C.

The compounds of the invention have been administered i.v. at days 1, 4 and 7 after the tumor transplantation. The extraosseous tumor mass has been measured at day 14 after tumor transplantation. The antitumor activity was determined as TWI% (tumor weight inhibition %) calculated according to the following formula:

$$\text{TWI\%} = \frac{(100 - \text{TW mean}_{\text{treated animals}})}{\text{TW mean}_{\text{controls}}} \times 100$$

wherein the TW for each animal is given by the formula:

$$\text{TW} = \frac{1}{2} (\text{ab})^2$$

in which a and b are respectively the maximum and minimum diameter of the tumor mass, expressed in mm.

The compounds of the invention resulted in addition active in an experimental model of human multiple myeloma on the lab animal.

11


The experiment is performed by inoculating intravenously (i.v.) the human multiple myeloma HS-Sultan cells in SCID rats (immunodeficient rats) at day 0, followed by treatment i.v. with a compound of the invention at days 15, 18 and 21.

The activity of the compounds of the invention was evaluated in relationship with the following parameters:

- Mean Survival Time (MST) in comparison with the not treated rats (which have a mean survival time of 30 days after tumor inoculation);

- evaluation of histological parameters (bone marrow invasion and degree of osteolytic lesions).

Table I summarizes the data for one representative compound of the invention in comparison with melphalan and with the prior art compound (WO 92/18512) of formula (A):



12
Table I - Antitumor activity against murine breast carcinoma Walker 256/B and human myeloma HS-Sultan

	Compound	Walker 256/B i.v. 1,4,7 dose TWI% Tox (mg/kg)			HS-Sultan i.v. + 15,18,21 dose TMS ¹ Tox (mg/kg)		
		20	89	0/8	60	70	1/6
10	compound (B)						
	compound (A)	10	66	1/8	15	55	1/5
	melfalan	2.8	71	11/144	6	59	1/5

15

¹MST = Mean Survival Time in days from the tumor inoculation (controls: MST 33-37).

The histopathological examination on some representative target organs, in the human multiple myeloma model, performed after 38 days from the treatment, showed the following tumor infiltration scores (- absence of infiltration; + slight infiltration; ++ middle to high infiltration):

		melfalan (A) (15 mg/kg)	(B) (60 mg/kg)
25	(6 mg/kg)		
	Sternum	+	+
	Backbone	+	+
	Backbone	-	+
	(soft tissues)		
30	Hind limbs	+	++
	Hind limbs	-	+

13

(soft tissues)

Kidneys

The data clearly show that the compound of the invention (compound (B)) has a selective inhibitory effect on the tumor infiltration which cannot be seen neither with melphalan nor with the prior art conjugate between melphalan and a gem-diphosphonic acid (compound (A)).

The compounds of the invention are endowed with a low acute toxicity and are well tolerated by the animal.

The high water solubility of the compound of the invention allows to prepare parenteral and oral pharmaceutical forms.

The compounds of formula (I), when administered to humans and animals bearing tumors susceptible of treatment with alkylating agents, in doses ranging from 1 mg to 1200 mg for square meter of body area, are able to induce regression of said tumor forms and to improve the bone tissue repair, avoiding in this way the pathological consequences caused by the bone lesions.

The effective dosage of the compounds of the invention can be determined by an expert clinician with known and conventional methods.

The correlation between dosages used for animals of various species and those for humans (as mg/m² of body area) is described in Freirich, E.J. et al., Cancer Chemother. Rep., 50, n. 4, 219-244, May 1966.

The tumors which can be treated by the compounds of the present invention are those tumors susceptible to the therapy with alkylating agents.

In particular, the multiple myeloma, osteosarcoma,

14

bone metastases, breast, ovary and testicular carcinomas can be advantageously treated.

The pharmaceutical compositions containing the compounds of formula (I) are encompassed in the scope of 5 the invention. Such pharmaceutical compositions may contain whatever amount of compounds of formula (I) able to exert an antitumor activity on the mammals against the tumors susceptible to the therapy with alkylating agents.

10 The pharmaceutical compositions may contain, in addition to at least one compound of formula (I), pharmaceutically compatible excipients, so that to allow the administration by every route, such as oral, parenteral, intravenous, intradermal, subcutaneous or 15 topical route, in liquid or solid form.

An administration route of the compounds of formula (I) is the oral route. Oral compositions will generally include an inert diluent or an edible carrier. They may be included in gel capsules or compressed into tablets. 20 Other oral administration forms are capsules, pills, elixirs, suspensions or syrups.

The tablets, pills, capsules and similar compositions may contain the following ingredients (in addition to the active principle): a binder such as 25 microcrystalline cellulose, tragacanth or gelatin; an excipient such as starch or lactose; a disintegrating agent such as alginic acid, primogel, maize starch and the like; a lubricant such as magnesium stearate; a fluidifier such as colloidal silicon dioxide; a 30 sweetening agent such as sucrose or saccharine or a flavouring agent such as mint flavour, methyl salicylate

15

or orange flavour. When the composition selected is in form of capsules, it can contain in addition a liquid carrier such as a fat oil. Other compositions can contain various material which change the physical form 5 thereof, for example coating agents (for tablets and pills) such as sugar or shellac. The material used in the preparation of the compositions should be pharmaceutically pure and non toxic at the dosages employed.

10 For the preparation of pharmaceutical compositions for the parenteral administration, the active ingredient can be included in solutions or suspensions, which can comprise in addition the following components: a sterile diluent such as water for injections, saline solution, 15 oils, polyethylene glycols, glycerin, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediamino tetraacetic acid; buffers such as acetates, citrates or phosphates and agents for 20 adjusting the tonicity of the solution, such as sodium chloride or dextrose. The parenteral preparation can be included in ampoules, mono-dose syringes, glass or plastic vials.

25 The invention is further illustrated by the following examples.

EXAMPLE 1

Synthesis of 2-[bis(diethoxyphosphoryl)methyl]maleic acid dimethyl ester

30 In a suspension of 1.33 g of sodium hydride (60% in oil) in 120 ml of toluene are added dropwise 10 g of

16

bis(diethoxyphosphoryl)methane dissolved in 20 ml of toluene. The reaction mixture is kept at room temperature under stirring for 1 hour, then it is cooled to 0°C and added dropwise with a solution of dimethyl acetylenedicarboxylate (5.17 g) in 20 ml of toluene. After 1 hour under stirring the reaction mixture is added with ethyl acetate until dissolution of the formed gummy solid occurs and it is washed firstly with 1 N hydrochloric acid (30 ml) then with water (2 x 30 ml). The organic phase is dried over sodium sulfate and the solvent is evaporated under reduced pressure, to give a residue (12.9 g) which, after purification by silica gel chromatography (300 g; eluent: petroleum ether/isopropanol 7 : 3) furnishes 9.6 g of pure product.

¹H NMR in CDCl₃: 1.35 ppm (m, 12 H); 3.77 ppm (s, 3 H); 3.80 ppm (s, 3 H); 3.85 ppm (t, 1 H); 4.20 ppm (m, 8 H); 6.9 ppm (t, 1 H).

EXAMPLE 2

Synthesis of 2-[bis(diethoxyphosphoryl)methyl]maleic acid.

A solution of 12.7 g of 2-[bis(diethoxyphosphoryl)methyl]maleic acid dimethyl ester in 76.8 ml of 1 N sodium hydroxide is kept under stirring for 96 hours, then the reaction mixture is washed twice with ethyl ether and is brought to pH 8.5 with 37% hydrochloric acid. The mixture is then concentrated to dryness and redissolved in 50 ml of methanol. After filtration of the formed sodium chloride, the solvent is evaporated under reduced pressure. The residue is treated with 125 ml of acetone,

17

to give, after filtration, 11.5 g of the product as disodium salt.

^1H NMR in D_2O : 1.30 ppm (m, 12 H); 4.17 ppm (m, 8H); 6.10 ppm (t, 1H); 6.56 ppm (t, 1H); 6.67 ppm (t, 1H).

5

EXAMPLE 3

Synthesis of 2-[bis(diethoxyphosphoryl)methyl]maleic anhydride.

A solution of 2.5 g of 2-[bis(diethoxyphosphoryl)methyl]maleic acid disodium salt in 50 ml of acetone is added with 2.13 g of para-toluenesulphonic acid. After 8 minutes under stirring, the formed sodium para-toluenesulphonate is separated by filtration and solvent is evaporated under reduced pressure. The residue is redissolved in 7.5 ml of anhydrous tetrahydrofuran and cooled to 0°C, then it is added dropwise with 3.8 ml of trifluoroacetic anhydride. The reaction mixture is refluxed for 30 minutes, then it is cooled to room temperature and concentrated to dryness. The residue is treated with ethyl ether, filtered and concentrated to dryness. This work up is repeated twice with toluene. 2.7 g of the product are obtained.

^1H NMR in CDCl_3 : 1.35 ppm (m, 12H); 3.95 ppm (t, 1H); 4.25 ppm (m, 8H); 7.12 ppm (t, 1H).

25

EXAMPLE 4

Synthesis of (2'E)-N-(3'-carboxy-4,4'-diethoxyphosphoryl-2'-butenoyl)-4-[bis(2-chloroethyl)aminol-L-phenylalanine.

In a solution of 2.9 g of melphalan in 290 ml of acetonitrile, 29 ml of water and 13 ml of triethylamine, are added dropwise 6 g of 2-

18

[bis(diethoxyphosphoryl)methyl]maleic anhydride dissolved in 60 ml of acetonitrile. The reaction mixture is kept under stirring for 3 hours, then the solvent is evaporated under reduced pressure. The residue is 5 dissolved in ethyl acetate and washed with 1 N hydrochloric acid (100 ml) and then with water (2 x 25 ml). The organic phase is dried over sodium sulfate and the solvent is evaporated under reduced pressure to give 10 7 g of residue which is purified by silica gel chromatography (350 g; eluent: from ethyl acetate to ethyl acetate/methanol 9 : 1) to give 3.48 g of the product.

¹H NMR in CDCl₃: 1.15-1.45 ppm (m, 12H); 2.75 ppm (dd, 1H); 3.1 ppm (dd, 1H); 3.55 ppm (m, 8H); 4.0-4.4 ppm (m, 15 8H); 4.82 ppm (m, 1H); 4.87 ppm (t, 1H); 6.55 ppm (d, 2H); 7.02 ppm (d, 2H); 7.55 ppm (t, 1H); 8.85 ppm (d, 1H).

EXAMPLE 5

Synthesis of (2'E)-N-(3'-carboxy-4,4'-dihydroxy-
20 phosphoryl-2'-butenoyl)-4-[bis(2-chloroethyl)aminol-L-
phenylalanine tetrasodium salt

A solution of (2'E)-N-(3'-carboxy-4,4'-diethoxyphosphoryl-2'-butenoyl)-4-[bis(2-chloroethyl)amino]-L-phenylalanine (3.23 g) in 177 ml of toluene, kept at 0°C under stirring, is added dropwise with 4.6 ml of trimethylsilyl iodide. The temperature is brought to room temperature and the reaction mixture is kept under stirring for 3 hours, then it is poured into 25 640 ml of methanol containing 2.68 g of sodium acetate. The solution is brought from pH 6.5 to pH about 7 with 1 N sodium hydroxide, then 64 ml of water are added and 30

19

the pH is again adjusted to pH 7.3. After 15 minutes under stirring, the mixture is filtered and the formed solid is washed with a few methanol. The solid is dried in an oven under vacuum overnight to give 2.43 g of the product.

5 ¹H NMR in D₂O: 3 ppm (m, 2H); 3.25 ppm (t, 1H); 3.75 ppm (s, 8H); 4.45 ppm (t, 1H); 6.35 ppm (t, 1H); 6.85 ppm (d, 2H); 7.25 ppm (d, 2H).

EXAMPLE 6


10 Following the methods described in examples 1-5 the following gem-diphosphonic acids are prepared:

- N-(3'-carboxy-4,4'-dihydroxyphosphoryl-4'-methyl-2'-butenoyl)-4-[bis(2-chloroethyl)amino]-L-phenylalanine tetrasodium salt;
- 15 - N-(3'-carboxy-4,4'-dihydroxyphosphoryl-2'-butenoyl)-4-[bis(2-chloroethyl)amino]-L-phenylalanine methyl ester, tetrasodium salt;
- N-(3'-carboxy-4,4'-dihydroxyphosphoryl-2'-butenoyl)-4-[bis(2-chloroethyl)amino]-L-phenylalanine 20 ethyl ester, tetrasodium salt;
- N-(3'-carboxy-4,4'-dihydroxyphosphoryl-4'-ethyl-2'-butenoyl)-4-[bis(2-chloroethyl)amino]-L-phenylalanine tetrasodium salt;
- N-(3'-carboxy-4,4'-dihydroxyphosphoryl-4'-butyl-2'-butenoyl)-4-[bis(2-chloroethyl)amino]-L-phenylalanine 25 ethyl ester, tetrasodium salt.

CLAIMS

1. Compounds of the general formula (I):

5



10 wherein:

- R, R₁ and R₂ are independently selected in the group consisting of hydrogen, methyl, ethyl, propyl, butyl, which can be linear or branched, with the proviso that R₁ cannot be tert-butyl;

15 - X is chlorine, bromine or iodine;

enantiomers, racemates, diastereoisomers and mixtures thereof, as well as salts thereof with pharmaceutically acceptable bases.

20 2. Compounds according to claim 1, in which X is chlorine.

3. Compounds according to claims 1 or 2, in which R, R₁ and R₂ are hydrogen.

25 4. Compounds according to claims 1 to 3, in which the stereochemistry of the carboxyl and carboxyamide groups on the C=C double bond is cis.


5. Compound according to claims 1 to 4, wherein said compound is:

- (2'E)-N-(3'carboxy-4,4'-diethoxyphosphoryl-2'-butenoyl)-4-[bis(2-chloroethyl)amino]-L-phenylalanine.

30 6. Process for the preparation of the compounds of claim 1, which comprises the following steps:

21


(a) reaction of a compound of formula (II):



5 in which the R' groups are linear (C_1-C_4)alkyl groups,
with a compound of formula (III):



in which the R₁' groups are linear (C_1-C_4)alkyl groups,
in the presence of a base, to give an intermediate of
10 formula (IV):




15

The compounds of formula (IV) are known compounds
[J. Org. Chem., 45(13), 2698-2703 (1980)].


(b) hydrolysis of the R₁' ester groups to give the
intermediates of formula (V):

20



25 optionally in the form of salts with the used base;

(c) cyclization reaction of intermediates of formula
(V) to give the anhydrides of formula (VI):




30

22

(d) condensation reaction of an anhydride of formula (VI) with a compound of formula (VII):


5



(VII)

to give the compounds of formula (VIII):

10




(VIII)

15

(e) optional esterification of the free carboxyl group of a compound of formula (VIII) to give the compounds of formula (IX):

20



25

(f) hydrolysis of the phosphonic esters of a compound of formula (VIII) or (IX) to give the wanted compounds of formula (I).

30

7. Process according to claim 6 for the preparation of the compounds of claim 1 with R = hydrogen, in which the

23

free carboxyl group of a compound of formula (VIII) with R = tert-butyl is esterified, followed by removal of the tert-butyl group.

8. Pharmaceutical formulation containing pharmaceutically effective amounts of one or more compounds according to claims 1 to 5 in admixture with excipients or additives.
- 5 9. Compounds according to claims 1 to 5 for the use as medicaments.
10. 10. Compounds according to claim 9, for the use as antitumor agents.
11. Compounds according to claim 10, in which the tumor to be treated is a multiple myeloma.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 98/01707

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07F9/38 A61K31/66 C07F9/40

According to International Patent Classification(IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07F A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 170 896 A (HENKEL KGAA ;DEUTSCHES KREBSFORSCH (DE)) 12 February 1986 cited in the application see the whole document ---	1-11
Y	WO 88 06158 A (STURTZ GEORGES) 25 August 1988 cited in the application see the whole document ---	1-11
Y	WO 92 18512 A (BOEHRINGER MANNHEIM ITALIA) 29 October 1992 cited in the application see the whole document ---	1-11
Y	WO 91 05791 A (BOEHRINGER BIOCHEMIA SRL) 2 May 1991 see the whole document ---	1-11
	-/-	

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
28 July 1998	06/08/1998
Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Beslier, L

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 98/01707

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 89 07453 A (HENKEL KGAA ;DEUTSCHES KREBSFORSCH (DE)) 24 August 1989 see the whole document -----	1-11
P,Y	WO 97 49711 A (BOEHRINGER MANNHEIM ITALIA S.P.A.) 31 December 1997 see the whole document -----	1-11

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/01707

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
EP 0170896	A	12-02-1986		DE 3425812 A JP 1961188 C JP 6051710 B JP 61063687 A US 4608368 A		16-01-1986 10-08-1995 06-07-1994 01-04-1986 26-08-1986
WO 8806158	A	25-08-1988		FR 2611203 A		26-08-1988
WO 9218512	A	29-10-1992		IT 1246777 B AT 144986 T AU 1459192 A DE 69215085 D DE 69215085 T EP 0580642 A ES 2096076 T JP 6506452 T US 5446187 A		26-11-1994 15-11-1996 17-11-1992 12-12-1996 03-04-1997 02-02-1994 01-03-1997 21-07-1994 29-08-1995
WO 9105791	A	02-05-1991		IT 1241674 B AT 137757 T AU 639495 B AU 6510890 A CA 2067191 A DE 69026964 D DE 69026964 T EP 0593437 A ES 2090143 T FI 921562 A JP 5500949 T US 5300671 A		27-01-1994 15-05-1996 29-07-1993 16-05-1991 13-04-1991 13-06-1996 24-10-1996 27-04-1994 16-10-1996 08-04-1992 25-02-1993 05-04-1994
WO 8907453	A	24-08-1989		DE 3804686 A EP 0401243 A JP 3504715 T		24-08-1989 12-12-1990 17-10-1991
WO 9749711	A	31-12-1997		IT MI961290 A AU 3260897 A		29-12-1997 14-01-1998